复方雪参胶囊治疗慢性无菌性前列腺炎的临床观察

目的观察复方雪参胶囊治疗慢性非细菌性前列腺炎(CAP)的临床疗效。方法将符合试验标准的130例,分成A组(75例)和B组(55例),再依据两组前列腺液中的白细胞含量进一步分为:A1组(41例)、A2组(34例)及B1组(24例)、B2组(31例)。A组服用复方雪参胶囊每次0.75g,3次/d,B组服用前列康片,每次3粒,3次/d,共30d。根据服药前后的各项观察指标的变化情况,进行疗效评定。结果A组及B组治疗前后病情比较,差异均有统计学意义(P<0.05),且A组治疗后的病情改善情况及总的疗效与B组比较,差异亦有统计学意义(P<0.05),但两药对A组Ⅲ级与B组Ⅲ级的疗效差异无统计学意义(P>0.05)。结论口服复方雪参胶囊及前列康均是CAP的有效治疗方法,复方雪参胶囊的疗效优于前列康,其对炎症性CAP与非炎症性CAP的疗效差异无统计学意义。

Clinical efficacy of Fufangxueshen capsule in the treatment of chronic abacterial prostatitis

Objective To evaluate the effectiveness of Fufangxueshen Capsule in the treatment of chronic abacterial prostatitis(CAP) patients.Methods One hundred thirty outpatients with a diagnosis standard consistent with NIH CAP were classified into group A(75 cases) and group B(55 cases).Two groups were divided further into group A1(41cases),group A2(34cases) and group B1(24cases),group B2(31 cases) according to leukocyte counts in EPS.The efficacy was evaluated by the varieties of Chronic Prostatitis Symptom Index(CPSI) after group A had been treated with Fufangxueshen Capsule and group B with Qianliekang Tablet for a month.Results There were statistically significant differences(P<0.05) in group A and group B between the pretreatment and posttreatment and the efficacy in group A showed significant difference(P<0.05) compared with group B after one month of treatment as well,but no difference(P>0.05) between ⅢA and ⅢB.Conclusion Both Fufangxueshen Capsule and Qianliekang Tablet are effective for the treatment of CAP and the former is superior to the latter,but ⅢA and ⅢB have no differences on the curative effect.